Friday, July 17, 2015

Faruqi & Faruqi Investigation: Receptos, Inc.

Faruqi & Faruqi, LLP Announces the Investigation of Receptos, Inc. (RCPT) Over the Proposed Sale of the Company to Celgene Corporation

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Receptos, Inc. (“Receptos” or the “Company”) (NASDAQ: RCPT) for potential breaches of fiduciary duties in connection with the sale of the Company to Celgene Corporation for approximately $7.3 billion in a cash deal. 
The Company’s stockholders will only receive $232 for each share of Company common stock they own. However, the offer has a negligible premium for a stock that has at least one analyst target price of $348 per share and a mean target price of $223.50 per share. Furthermore, the Company’s share price is expected to continue climbing.
If you own common stock in Receptos and wish to obtain additional information and protect your investments free of charge, please fill out the form below or contact F&F's Juan E. Monteverde, Esq. either via e-mail at or by telephone at (877) 247-4292 or (212) 983-9330. 

No comments:

Post a Comment